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DICARLO, L.A. ET AL.: Driving Restrictions Advised by Midwestern Cardiologists Implanting Cardiover-
ter Defibrillators: Present Practices, Criteria Utilized, and Compatibility with Existing State Laws. Al-
though some patients remain at risk of losing physical control or collapsing after implantation of a
cardioverter defibrillator for sustained ventricular arrhythmias, little is known about restrictions advised
by arrhythmia specialists to patients with implanted devices concerning physical activities such as
driving. In this study, all of the 58 cardiologists implanting cardioverter de/ibrillators in three contiguous
midwestern states were surveyed to determine present practices and the compatibility of these practices
with existing state law. 0/the 51 respondents (88%J, 27 cardiologists f53%J advised only those implanted
patients who had had arrhythmia-induced presyncope or physical collapse to cease driving. Twenty
two of the remaining cardiologists (43%) advised all implanted patients to cease driving, whereas two
cardiologists f4%j never advised any implanted patient to restrict driving. Permanent driving abstinence
was advised by seven of the responding cardiologists (14%j, while temporary driving abstinence for
periods of 2-12 months (mean 6 ± 3 months] was recommended by the remaining 42 respondents (82%)
who advised against driving. The criteria utilized, driving restrictions advised, and durations advised
for driving restrictions were not uniform in any of the 13 surveyed university and nonaffiliated cardiology
practices with >2 implanting cardiologists. Overall, 38 cardiologists [74%] advised against driving and
recommended durations that equaled or exceed their state's minimuni legal requirements, although only
27 of the 51 cardiologists (53%J based their practice upon knowledge of their state's driving laws. The
results of this survey suggest that the majority of cardiologists who implant cardioverter defibrillators
advise their patients against driving postoperatively. However, the criteria and durations utilized in
advising driving abstinence are not uniform and do not always conform with existing state laws. (PACE,
Vol. 15, August 1992]
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terventional therapy. ̂ ~̂  While these implantable
devices are therapeutic, they are not prophylactic.
Some patients remain at risk of losing physical
control or losing consciousness at the time of sub-
sequent device discharges.^°~^^ Little is known,
however, about postoperative restrictions advised
by arrhythmia specialists concerning activities
such as driving or the compatability of this advice
with existing state laws.
In this study, a regional survey was made of
all implanting cardiologists in three contiguous
midwestern states to determine their present prac-
tices when advising driving restrictions after car-
dioverter defibrillator implantation, the criteria
utilized for advising driving restrictions, and the




All cardiologists implanting cardioverter de-
fibrillators in the contiguous states of Indiana,
Michigan, and Ohio were identified from directo-
ries available from the North American Society of
Pacing and Electrophysiology (NASPE, Newton
Upper Falls, MA, USA], and provided by Cardiac
Pacemakers, Inc. (St. Paul, MN, USA) who were
the sole suppliers of commercially available im-
plantable cardioverter defibrillators in the United
States at the time of this survey.
Survey Methods
The survey was conducted by telephone. At-
tempts were made to contact each implanting car-
diologist a minimum of three times during the
4-week survey period. Each implanting cardiolo-
gist was informed of the nature of the survey and
asked to give his/her verbal consent to participate
in the survey before being questioned. Responses
to each question were recorded as follows:
(A) In which state do you practice?
(1) Indiana (2) Michigan (3) Ohio
(Bj Do you advise patients to cease driving
after implantation of an automatic cardioverter
de/ibriJJator?
(1) Yes (2) No
(C) How often do you make such a recom-
mendation?
(1) Always (2) Sometimes (3) Never
(DJ If your response to (C) is SOMETIMES,
which of the following criteria do you utilize in
making your recommendation (you may use more
than one]?
(1) Near-loss or loss of consciousness dur-
ing spontaneous clinical arrhythmia before device
implantation
(2) Near-loss or loss of consciousness dur-
ing induced arrhythmia before device implan-
tation
(3) Near-loss or loss of consciousness dur-
ing postoperative device testing
(EJ What is the minimum duration of your
recommendation against driving?
(1) Months (2) Permanent
fFj Assume that the device you implanted is
discharging appropriately for the arrhythmia(s)
you intended to treat. Which of the following is
the minimum criterion you utilize during out-of-
hospitaJ follow-up to subsequently advise a longer
period of driving abstinence (pJease choose only
one]?
(1) A single device discharge without near-
loss or loss of consciousness
(2) Multiple device discharges without
near-loss or loss of consciousness
(3) Near-loss or loss of consciousness at the
time of device discharge
(GJ Which of the following would you use to
characterize your patients who have had an auto-
matic cardioverter defibrillator implanted (you
may use more than one]?
[1] Urban (2) Suburban (3] Rural
(Hj Are 25 or more percent of your patients
rural?
(1) Yes (2] No
(IJ Are there any driving laws concerning ar-
rhythmias and loss of physical control or loss of
consciousness in your state which have helped to
guide your driving recommendation(sj?
(1) Yes (2) No (3) Don't know
(/] If your answer to (Ij is YES, what driving
restriction(sj do these laws advise or require?
(ANSWER]
(Kj Which of the following characterizes the
institution where you implant cardioverter de-
fibrillators (please choose only one)?
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(1) University hospital or medical center
(2) University-affiliated hospital or medi-
cal center
(3] Private hospital or medical center
Content of State Laws
Information concerning the actual existence
and content of state driving laws concerning ar-
rhythmias and loss of physical control or loss of
consciousness were obtained from the Licensing
Bureau, Department of Motor Vehicles, Indianapo-
lis, Indiana; the Department of State, Lansing,
Michigan; and the Bureau of Motor Vehicles, De-
partment of Highway Safety, Columbus, Ohio. The
information from these three sources was used as
a basis for determining the correct responses to
survey questions I and J.
Data Recording and Analysis
All responses to all questions were recorded
anonymously. The response to all questions were
tabulated subsequently, and statistical analysis
was performed utilizing paired and unpaired Stu-
dent's t-tests and tests of p for binomial distribu-
tion where appropriate.^^
Results
The results of the survey are summarized in
Tables I and IL
Physicians Surveyed
A total of 58 implanting cardiologists were
identified from the sources utilized for the survey.
Fifty one of the 58 identified cardiologists (88%]
replied to the survey. Twenty-eight respondents
(55%) were implanting cardiologists at university
or university-affiliated hospitals. The other 23 re-
spondents practiced in nonaffiliated hospitals.
The survey included seven university and six non-
affiliated cardiology groups where s two im-
planting cardiologists practiced together.
Twenty five of the respondents (49%) cared
for patients living in almost exclusively urban or
suburban locations, while the other 26 implanting
cardiologists (51%) had 2:25% of their patients liv-














































Criteria for Driving Restrictions
Twenty-two implanting cardiologists (43%)
advised all implanted patients to abstain from
driving, whereas two implanting cardiologists
(4%) never advised any implanted patient to re-
strict driving.
The remaining 27 implanting cardiologists
(53%) advised driving abstinence only to those im-
planted patients who had had arrhythmia-induced
near-loss or loss of consciousness. Twenty three of
these 27 implanting cardiologists (85%) based
their recommendation for driving abstinence upon
the occurrence of near-loss or loss of conscious-
ness during a spontaneous or induced arrhythmia
before device implantation, whereas the other four
cardiologists based their recommendation solely
upon the occurrence of near-loss or loss of con-
sciousness during postoperative device testing.
Duration
Permanent driving abstinence was advised by
seven of the responding cardiologists (14%), while
temporary driving abstinence for periods of 2—12
months (mean 6± 3 months) was recommended
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by the remaining 42 respondents (82%] who ad-
vised against driving.
Criteria for subsequently advising a longer du-
ration of driving restriction were: (1) a single out-
of-hospital device discharge (15 physicians, 29%);
(2) multiple device discharges (12 physicians,
24%); or (3) hemodynamic collapse at the time of
device discharge (17 physicians, 35%) occurring
during the initial period of driving abstinence.
Comparison with State Laws
Overall, 27 of the 51 physicians surveyed
(53%) knew the content of their state's laws con-
cerning arrhythmias and temporary loss of physi-
cal control or loss of consciousness, and advised
their patients concerning driving abstinence based
upon that knowledge.
Eleven of the remaining physicians (22%),
who incorrectly answered the survey questions
concerning such laws, nevertheless advised their
patients against driving for durations that equaled
or exceeded the minimum legal duration required
by their state.
Correlation of Results
The criteria utilized, driving restrictions ad-
vised, and durations advised for driving restric-
tions were not uniform in any of the 13 university
and nonaffiliated cardiology practices surveyed.
No significant differences were found be-
tween (1) physicians practicing in academic/uni-
versity-affiliated hospitals versus physicians prac-
ticing in nonaffiliated hospitals or (2) physicians
with almost exclusively urban/suburban patients
versus physicians with S25% rural patients, with
regard to: (a) making recommendations against
driving to all versus selected implanted patients,
(b) the criteria utilized for making a recommenda-
tion, (c) the duration recommended for driving ab-
stinence, (d) the criteria for extending the duration
of driving abstinence, or (e) knowledge of the exis-
tence and specific content of laws in the state in
which the physicians practiced.
Discussion
The modern management of paroxysmal ven-
tricular fibrillation and sustained ventricular
tachycardia includes implantation of cardioverter
defibrillators in patients whose arrhythmias are
not amenable to pharmacological treatment or al-
ternative therapies such as percutaneous or surgi-
cal ablation.^~^ Patient-device interactions are
complex, however, and have several limitations.
The reliability of tachycardia detection and
termination by presently implanted cardioverter
defibrillators is not consistent. Twenty-seven per-
cent to 41% of discharges from presently available
commercial cardioverter defibrillators have been
reported to occur as a result of misdiagnosis of
sinus rhythm, sinus tachycardia, or supraventricu-
lar tachycardia as ventricular tachycardia or ven-
tricular fibrillation, or in response to nonsustained
supraventricular tachycardia or ventricular tachy-
cardia. '̂̂ '̂ '̂ ^ Some patients experience transient
incapacitation from the cardioverter defibrillator
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discharge itself.^'' For others, the cardioverter de-
fibrillator discharge may actually result in provo-
cation, rather than termination, of arrhythmias
that cause hemodynamic collapse.^^
Not all patients experience near-loss or frank
loss of consciousness due to their ventricular ar-
rhythmias prior to cardioverter defibrillator im-
plantation. However, the ability to maintain con-
sciousness during subsequent, spontaneous ar-
rhythmia recurrences, that cause cardioverter
defibrillator discharge varies.^"'^^ The ability to
maintain consciousness at the time of initial,
spontaneous out-of-hospital cardioverter defibril-
lator discharges does not guarantee consciousness
at the time of a subsequent cardioverter defibrilla-
tor discharges.^°
The complexity of implantable devices con-
tinues to increase. Later generation devices that
now incorporate programmed electrical stimula-
tion with automatic cardioversion and defibrilla-
tion are being implanted in the United States and
abroad.^^'^^ Like implantable devices capable of
cardioversion or defibrillation alone, these newer
devices have the potential of providing inappro-
priate therapy as a result of false-positive diag-
noses of sustained ventricular arrhythmias.^^ Like
commercially available cardioverter defibrillators,
they have the potential of provoking rather than
terminating arrhythmias capable of causing physi-
cal collapse or loss of physical control.^^'^^
Postoperative recommendations concerning
physical activities such as driving, therefore,
might be considered advisable for at least some
patients. The results of the present study suggest
that the majority of cardiologists who implant au-
tomatic cardioverter defibrillators do make recom-
mendations concerning driving after device im-
plantation. However, the criteria utilized for mak-
ing a recommendation, determining the duration
of driving abstinence, and subsequently extending
the duration of driving abstinence is not uniform
and does not always conform to existing state
laws.
The state laws themselves vary significantly.
One recent survey of state regulations determined
no legal consensus concerning driving restrictions
after cardioverter defibrillator implantation.^''
Only one of the three states in the present study
had a law that explicitly prohibits driving after
impairment or loss of consciousness until the con-
dition(s) causing it has been "corrected, cured, or
controlled, or [has] abated for not less than 6
months."^^ The other two states provided for issu-
ance of restricted licenses that limit routes of
travel for a minimum of 6 months. None of the
three states had laws requiring either the physi-
cian or the patient to notify the state's licensing
bureau of the patient having such a condition, or
of the patient having been advised against driving
at the time of the condition's discovery. None of
the three states had any laws specifically govern-
ing individuals who have had a cardioverter defi-
brillator implanted for control of cardiac arrhyth-
mias. Uncertainty with regard to this issue is also
reflected in the recently published NASPE policy
statement,^^ which contains no guidelines or con-
sensus recommendation regarding the operation
of automobiles or other machinery after cardiover-
ter defibrillator implantation.
The present study is the first geographic sur-
vey that comprehensively characterizes physician
practices concerning driving restrictions advised
to patients with implanted cardioverter defibrilla-
tors. Randomly selected arrhythmia specialists
were questioned in another recent study about re-
sumption of driving after implantation of a cardio-
verter defibrillator in patients who had survived
an out-of-hospital cardiac arrest.^'' In contrast to
the the findings of the present study, fewer re-
spondents to the earlier survey (60%) believed that
driving should be restricted, whereas a greater pro-
portion of the respondents to the earlier survey
[one third] believed that driving restrictions, when
made, should be permanent. Among this earlier
study's limitations were its small physician sam-
ple size relative to the geographic area repre-
sented, its failure to adequately represent any one
region or all regions of the United States, its lack
of adequate representation of urban or academic
medical centers, its consideration only of survi-
vors of out-of-hospital cardiac arrest, and its fail-
ure to distinguish between driving restriction as
opposed to cessation. The earlier study did not
make any assessment of the actual driving restric-
tions advised by the surveyed physicians, the cri-
teria utilized, or the durations advised when the
restriction was temporary, and it did not deter-
mine the compatibility of individual physician
practices with the laws of the states in which the
physicians practiced.
Additional and larger studies will be neces-
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sary to determine tbe scope and prevalence of
present physician practices concerning driving or
tbe operation of otber macbinery after tbe implan-
tation of antitacbycardia devices, as well as tbe
socioeconomic and public bealtb impacts of tbese
practices. Ultimately, tbe development and imple-
mentation of a more uniform and consistent set of
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